anti-IL-23 monoclonal antibody

Anti-IL-23 monoclonal antibodies represent a class of targeted biologic therapies that neutralize the cytokine interleukin-23 (IL-23) by binding to its unique p19 subunit. IL-23 is a key regulatory cytokine involved in the differentiation and survival of Th17 cells, which produce pro-inflammatory mediators like IL-17 and IL-22. By blocking this pathway, anti-IL-23 antibodies effectively reduce chronic inflammation in tissues such as the skin and gut. This class includes several approved therapies, such as guselkumab, risankizumab, and tildrakizumab, which are standard-of-care treatments for moderate-to-severe plaque psoriasis, psoriatic arthritis, and inflammatory bowel diseases like Crohn's disease and ulcerative colitis. In the provided context, an anti-IL-23 mAb is used as a benchmark to demonstrate the superior efficacy of a dual IL-22/IL-23 bispecific antibody in preclinical models of psoriasis.

Other names

IL-23 inhibitorIL23 inhibitorIL 23 inhibitoranti-IL-23 mAbanti-IL23 mAbanti-IL 23 mAbIL-23p19 inhibitorIL23p19 inhibitorIL 23p19 inhibitorIL-23 antagonistIL23 antagonistIL 23 antagonist